SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial

Background: The antiviral effects of Novaferon, a potent antiviral protein drug, on COVID-19 was evaluated in the laboratory, and in a randomized, open-label, parallel-group trial. Methods: In the laboratory, Novaferon's inhibition of viral replication in cells infected with SARS-CoV-2, and pre...

Full description

Autores:

Tipo de recurso:

Article of investigation

Fecha de publicación:

2020

Institución:

Universidad de Bogotá Jorge Tadeo Lozano

Repositorio:

Expeditio: repositorio UTadeo

Idioma:

eng

OAI Identifier:

oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/14033

Acceso en línea:

https://doi.org/10.1016/j.ijid.2020.07.053
http://hdl.handle.net/20.500.12010/14033

Palabra clave:

COVID-19
SARS-CoV-2
Novaferon
Antiviral drug
Lopinavir/Ritonavir
Viral clearance
Aerosolized inhalation
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus

Rights

License

Abierto (Texto Completo)